Overview

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy of CAR-T treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Collaborator:
The Second Hospital of Hebei Medical University
Treatments:
Cyclophosphamide
Fludarabine